Comparison
Ipamorelin vs N-Acetyl Cysteine
Side-by-side of Ipamorelin and N-Acetyl Cysteine. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
N-Acetyl Cysteine
NAC supplement benefits cover glutathione synthesis, liver and antioxidant support, and hangover recovery. Evidence strongest at 1200-2400 mg/day.
Effects at a glance
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
N-Acetyl Cysteine
- •Replenishes intracellular glutathione by supplying cysteine, the rate-limiting amino acid for synthesis
- •First-line antidote for acetaminophen toxicity, restoring hepatic glutathione before fulminant injury occurs
- •Reduces sputum viscosity in chronic bronchitis and COPD at 600 to 1200 mg/day over months
- •Modest symptom reductions in OCD and trichotillomania at 1200 to 2400 mg/day across small RCTs
- •Mixed evidence for psychiatric adjunct use in bipolar depression and schizophrenia negative symptoms
- •Inhaled forms can trigger bronchospasm in active asthma; oral use is the standard biohacker route
Side-by-side
| Attribute | Ipamorelin | N-Acetyl Cysteine |
|---|---|---|
| Category | peptide | supplement |
| Also known as | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 | NAC |
| Half-life (hr) ↗ | 2 | 5.6 |
| Typical dose (mg) ↗ | 0.2 | 1200 |
| Dosing frequency | 2-3x daily | 1 to 3 times daily, split dosing preferred |
| Routes | subcutaneous, intravenous | oral, iv |
| Onset (hr) | 0.25 | 1 |
| Peak (hr) | 1 | 2 |
| Molecular weight | 711.86 | 163.19 |
| Molecular formula | C38H49N9O5 | C5H9NO3S |
| Mechanism | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. | Deacetylated to cysteine, the rate-limiting precursor for glutathione synthesis; also directly scavenges reactive oxygen species and modulates glutamate signaling. |
| Legal status | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA | OTC in most jurisdictions; restricted periods in US history (FDA reclassified 2022) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | OTC supplement (US, post-2022); Rx indications also exist (acetaminophen overdose, mucolytic) |
| Pregnancy | Insufficient data; not recommended | Used clinically in pregnancy for specific indications; consult clinician |
| CAS | 170851-70-4 | 616-91-1 |
| PubChem CID | 11338566 | 12035 |
| Wikidata | Q1666741 | Q413299 |
Safety profile
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
N-Acetyl Cysteine
Common side effects
- sulfur-like taste or odor
- nausea
- flatulence
- diarrhea
Contraindications
- active asthma attack (inhaled form can trigger bronchospasm)
- known NAC hypersensitivity
Interactions
- nitroglycerin: potentiates vasodilation, risk of hypotension and headache(moderate)
- activated charcoal: reduces NAC absorption when used for acetaminophen overdose(moderate)
- anticoagulants: theoretical additive antiplatelet effect at high doses(minor)
Which Should You Take?
N-Acetyl Cysteine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC, oral dosing, with a Tier-A outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is body composition, pick Ipamorelin.
- → If your priority is healthspan extension, pick N-Acetyl Cysteine.
- → If your priority is liver function, pick N-Acetyl Cysteine.
Edge case: If you want to avoid research-only / gray-market sourcing, N-Acetyl Cysteine is the more accessible choice.
Default choice: N-Acetyl Cysteine. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Ipamorelin and N-Acetyl Cysteine?
Ipamorelin and N-Acetyl Cysteine differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Ipamorelin or N-Acetyl Cysteine?
Ipamorelin half-life is 2 hours; N-Acetyl Cysteine half-life is 5.6 hours.
Can you stack Ipamorelin with N-Acetyl Cysteine?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper